Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Semaglutide Injection Compared to Ozempic in Type 2 Diabetes
CTR20230379Phase 3Completed
- Sponsor
- Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Federal Biotechnology (Zhuhai Hengqin) Co., Ltd.. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20230379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230379.